InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,576.92
(
-1.01%
)
US TECH 100
19,667.40
(
-2.24%
)
Dow Jones
39,777.11
(
0.14%
)
Brent Oil
84.93
(
-0.14%
)
Bitcoin
57,803.76
(
0.08%
)
Post# of 252571
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120028
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 221611

Thursday, 10/25/2018 11:41:58 AM

Thursday, October 25, 2018 11:41:58 AM

Post# of 252571
US FoB programs have been disappointments, by and large. However, the impediment to commercial success has not been FDA approval, but rather the extensiveness of blocking IP (e.g. ABBV's Humira) and PBM contracting that seeks to lock out an FoB (e.g. PFE-JNJ lawsuit on Remicade).

In the EU and other parts of the world, more FoBs have launched and garnered respectable market share.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up